NO20031939D0 - Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4- diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler - Google Patents

Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4- diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler

Info

Publication number
NO20031939D0
NO20031939D0 NO20031939A NO20031939A NO20031939D0 NO 20031939 D0 NO20031939 D0 NO 20031939D0 NO 20031939 A NO20031939 A NO 20031939A NO 20031939 A NO20031939 A NO 20031939A NO 20031939 D0 NO20031939 D0 NO 20031939D0
Authority
NO
Norway
Prior art keywords
diaminocyclohexyl
purines
disubstituted
acyl
trans
Prior art date
Application number
NO20031939A
Other languages
English (en)
Other versions
NO20031939L (no
Inventor
David Roger Borcherding
Jennifer Ann Dumont
Norton P Peet
Paul S Wright
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0117075.2A external-priority patent/GB0117075D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20031939D0 publication Critical patent/NO20031939D0/no
Publication of NO20031939L publication Critical patent/NO20031939L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20031939A 2000-10-31 2003-04-29 Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler NO20031939L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24456700P 2000-10-31 2000-10-31
GBGB0117075.2A GB0117075D0 (en) 2000-10-31 2001-07-13 Acyl and sulfonyl derivatives of 6, 9-distributed 2-(trans-1, 4-diaminocyclohexyl)-purines and their use as antiproliferative agents
PCT/US2001/044835 WO2002042303A2 (en) 2000-10-31 2001-10-31 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents

Publications (2)

Publication Number Publication Date
NO20031939D0 true NO20031939D0 (no) 2003-04-29
NO20031939L NO20031939L (no) 2003-06-19

Family

ID=26246308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031939A NO20031939L (no) 2000-10-31 2003-04-29 Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler

Country Status (14)

Country Link
EP (1) EP1377579B1 (no)
JP (1) JP4348081B2 (no)
AT (1) ATE426603T1 (no)
AU (2) AU3938802A (no)
BR (1) BR0115080A (no)
CA (1) CA2427338C (no)
DE (1) DE60138140D1 (no)
DK (1) DK1377579T3 (no)
ES (1) ES2324763T3 (no)
IL (1) IL155590A0 (no)
MX (1) MXPA03003774A (no)
NO (1) NO20031939L (no)
NZ (1) NZ525264A (no)
WO (1) WO2002042303A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CA2525207A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) * 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
HUP0100931A3 (en) * 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2001044260A2 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof

Also Published As

Publication number Publication date
EP1377579A2 (en) 2004-01-07
BR0115080A (pt) 2003-09-23
EP1377579B1 (en) 2009-03-25
WO2002042303A3 (en) 2003-10-30
DK1377579T3 (da) 2009-08-31
JP2004517075A (ja) 2004-06-10
ES2324763T3 (es) 2009-08-14
IL155590A0 (en) 2003-11-23
AU3938802A (en) 2002-06-03
NZ525264A (en) 2005-12-23
DE60138140D1 (de) 2009-05-07
AU2002239388B2 (en) 2006-05-25
CA2427338A1 (en) 2002-05-30
NO20031939L (no) 2003-06-19
CA2427338C (en) 2008-06-10
MXPA03003774A (es) 2003-07-28
WO2002042303A2 (en) 2002-05-30
JP4348081B2 (ja) 2009-10-21
ATE426603T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
NO20031939L (no) Acyl- og sulfonylderivater av 6,9-disubstituerte 2-(trans-1,4-diaminocykloheksyl)-puriner og deres anvendelse som antiproliferative midler
NO331175B1 (no) Kinazolin-derivater som angiogenese-inhibitorer og mellomprodukter derav.
DK1309575T3 (da) Biphenylderivater og deres anvendelse som aktivatorer af PPAR-gamma-receptorerne
DK0988292T3 (da) Piperazinderivater og deres anvendelse som antiinflammationsmidler
FI925167A (fi) 2-substituerade sackarinderivat, som aer inhibitorer foer proteolytiska enzymer
IT1309590B1 (it) Derivati di 1-alcossi-polialchil-piperidine e loro impiego comeregolatori della polimerizzazione.
NO20005265L (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
MA25836A1 (fr) Derives de pyridine avec une activite inhibitrice de ikb-kinase (ikk-b)
NO20020683D0 (no) Arylmetylkarbonylaminotiazolderivater og deres anvendelse som antitumormidler
DK0797439T3 (da) Anvendelse af pramipexol som et neurobeskyttende middel
NO20023613L (no) Nikotinamid benzokondenserte heterocyclylderivater nyttige som selektive inhibitorer av PDE4
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
NO20032181L (no) Anvendelse av CCI-779 som et antineoplastisk middel
ITRM20010356A0 (it) "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
DK0625987T3 (da) Aminoacetylmercaptoacetylamid-derivater, der kan anvendes som inhibitorer af enkephalinase og ACE
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
ATE332903T1 (de) Kondensierte pyridoindolderivate
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20025150D0 (no) 2-acylindolderivater og deres anvendelse som antitumormidler
DK1073416T3 (da) Anvendelse af NO som anti-inflammatorisk middel
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ATE302776T1 (de) Kondensierte pyridoindolderivate
NO20030998D0 (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
NO20043173L (no) Benzotiazol- og benzoksazol-4,7-dionderivater og deres anvendelse som CDC25-fosfataseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application